---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/36092698.md"
description: "$Arcturus Therapeutics(ARCT.US) For a biopharmaceutical company with significant platform value, it's hard to imagine that its stock price would fall below its net cash on hand. Moreover, its COVID-19 vaccine has already been commercialized in Japan and the EU, and its commercialization revenue and future milestone payments are also substantial. Only one of its two mRNA drug pipelines seems to be progressing less than ideally. I just want to say, in the future, someone will surely regret missing out, hahaha, mark my words."
datetime: "2025-11-06T15:58:41.000Z"
locales:
  - [en](https://longbridge.com/en/topics/36092698.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/36092698.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/36092698.md)
author: "[砺身济世](https://longbridge.com/en/profiles/19728405.md)"
---

# $Arcturus Therapeutics(ARCT.US) For a biopharmaceu…


### Related Stocks

- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)

## Comments (3)

- **米斯卡 · 2025-11-08T12:32:25.000Z**: Bought seventy or eighty 12.5 calls of 1219, feeling a bit risky~
  - **砺身济世** (2025-11-08T16:55:40.000Z): This is a bit dangerous, and it's dangerous in the short term
  - **ckone** (2025-11-10T14:37:58.000Z): Hope the earnings report is strong tomorrow